Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 33.85
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Parmax Pharma Ltd. engages in the manufacture of bulk drugs like ampicilin, amoxycillin, cephalexin, and nalidixic acid. The company also plans to extend its activities in formulation of tablets, capsules, ointments, & injectable. The company was founded on November 2, 1994 and is headquartered in Rajkot, India.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell